New approaches in the treatment of advanced prostate cancer:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
2006
|
| Schriftenreihe: | Urologic clinics of North America
33,2 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIII S., S. 133 - 278 Ill., graph. Darst. |
| ISBN: | 141603563X |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV021611216 | ||
| 003 | DE-604 | ||
| 005 | 20140207 | ||
| 007 | t | ||
| 008 | 060608s2006 ad|| |||| 00||| eng d | ||
| 020 | |a 141603563X |9 1-4160-3563-X | ||
| 035 | |a (OCoLC)255666165 | ||
| 035 | |a (DE-599)BVBBV021611216 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-29 |a DE-19 | ||
| 084 | |a YK 7500 |0 (DE-625)153783:12905 |2 rvk | ||
| 245 | 1 | 0 | |a New approaches in the treatment of advanced prostate cancer |c guest ed. Joseph A. Smith ... |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2006 | |
| 300 | |a XIII S., S. 133 - 278 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Urologic clinics of North America |v 33,2 | |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Prostatakrebs |0 (DE-588)4047511-6 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Prostatakrebs |0 (DE-588)4047511-6 |D s |
| 689 | 0 | 1 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 700 | 1 | |a Smith, Joseph A. |d 1949- |e Sonstige |0 (DE-588)1024897761 |4 oth | |
| 830 | 0 | |a Urologic clinics of North America |v 33,2 |w (DE-604)BV000001584 |9 33,2 | |
| 856 | 4 | 2 | |m Digitalisierung UBRegensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014826424&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-014826424 | ||
Datensatz im Suchindex
| _version_ | 1804135397362499584 |
|---|---|
| adam_text | NEW APPROACHES IN THE TREATMENT OF ADVANCED PKOSTATK CANCER
CONTENTS
Foreword xi
Martin I. Resnick
Preface xiii
Joseph A. Smith, Jr and Sam S. Chang
The Evolution of Imaging in Advanced Prostate Cancer
Michael J. Manyak,
and Erik S. Storm
Medical advances will be driven by the enhancement of imaging for diagnosis, refine¬
ment of treatment, and evaluation of treatment efficacy. The convergence of technology
in materials science, biology, and the computer industry has greatly advanced diagnostic
imaging. Precision in control of the spatial and temporal properties of light and its het¬
erogeneous scattering properties have extended our capability for imaging. Refinements
in radioimmunoscintigraphy for image acquisition, fusion of images, and outcome data
now suggest use for image-guided therapy. Novel MRI agents appear to provide signif¬
icant imaging capabilities to detect malignant lymph nodes. Future applications of opti¬
cal coherence tomography, electron paramagnetic resonance imaging, nanotechnology,
molecular imaging, and hyperspectral spectroscopy promise further refinements to
image tissues for diagnosis.
Biochemical Recurrence after Localized Treatment
Christopher L. Amling
The quoted incidence of biochemical recurrence (BCR) after localized treatment varies
significantly and depends on numerous well-known prognostic factors; however, it
likely occurs in at least 30%-40% of patients who receive localized treatment. Because
the clinical significance of BCR is often unclear, and depends in many cases on unknown
factors, it is difficult to select the best treatment and determine when best to institute that
therapy. This review examines some of the issues associated with BCR and attempts to
shed some light on this common but controversial clinical scenario. Some treatment stra¬
tegies discussed in this article include salvage radiotherapy after radical prostatectomy,
salvage therapy after radiotherapy, and hormonal therapy.
Combined Androgen Blockade: An Update
Laurence
The use of combined androgen blockade therapy in prostate cancer management re¬
mains controversial. This article reviews the effect of the different non-steroid androgens
VOLUME
in blocking androgen-independent activation of the androgen receptor in the androgen-
depleted environment, and the potential benefit of bicalutamide in comparison to the
first generation of anti-androgens (flutamide and nilutamide). An estimate of the benefit
of combined therapy with bicalutamide suggests there is a high probability that bicalu¬
tamide
This treatment must be balanced against the potential for an increase in side-effects and a
consequent adverse effect on the patient s quality of
Intermittent Androgen Deprivation: Clinical Experience and Practical
Applications
Jonathan L. Wright, Celestia S. Higano, and Daniel W. Lin
Prostate cancer is more frequently being diagnosed at an earner age, men are dying of
prostate cancer at an older age, and men are now treated with androgen deprivation
for biochemical relapse. As a result, the amount of time that patients are potentially sub¬
jected to androgen deprivation is increasing. Intermittent androgen deprivation (IAD)
has been investigated as a potential alternative to continuous androgen deprivation
(CAD) in order to improve quality of
gen independence. Along with the increased use of primary hormonal therapy in clini¬
cally localized prostate cancer, IAD may supplant the traditional surgical or
radiotherapy options, specifically in men who have underlying co-morbidities and de¬
creased
lend insight into the utility, efficacy, and feasibility of IAD versus CAD. This article dis¬
cusses the theoretical benefits and rationale of IAD and reviews the completed and on¬
going IAD trials. Finally, the controversies, practical applications, and future directions
of IAD are addressed.
Managing Complications of Androgen Deprivation Therapy
for Prostate Cancer
Jeffrey M. Holzbeierlein
With the increase in the number of prostate cancer cases seen in the United States, the use
of androgen deprivation therapy (ADT) as a form of treatment has continued to rise.
With the increasing use of ADT, it is important for the urologist to recognize the potential
side effects from the use of ADT and ways in which to minimize or
from these side effects. This article describes the potential complications of ADT and
the recommendations for treatment or prevention of these complications. In addition,
we examine the role of nontraditional forms of ADT and the potential benefits they offer.
The Role of Bisphosphonates in Preventing Skeletal Complications
of Hormonal Therapy
Scott M. Gilbert and James M. McKiernan
Androgen deprivation therapy (ADT) is associated with a significant decrease in bone
mineral density (BMD), and continued exposure seems to increase the risk of osteoporo-
tic fracture in men who have prostate cancer treated with this strategy. Men who have
prostate cancer may have low BMD before initiation of ADT. Bisphosphonates are pyr-
ophosphate analogs that decrease bone
osteoclast activity and proliferation. Several bisphosphonates have been evaluated in
randomized clinical trials, and the cumulative data show that these medications increase
or maintain BMD in men receiving ADT for prostate cancer. The effect on clinical frac¬
tures has not been assessed adequately, but bisphosphonates offer an important potential
treatment modality to reduce the risk of osteoporotic fracture in this population of men.
CONTENTS
Mechanisms Leading to the Development of Hormone-Resistant
Prostate Cancer
Susan
Advanced and metastatic prostate cancers remain potentially lethal tumors. Although
androgen deprivation therapy remains the most effective treatment, patients who pro¬
gress to androgen independence die of their disease. This article focuses on the mechan¬
isms by which hormone resistance develops, including the reactivation of androgen
receptor during androgen deprivation therapy, the role of cancer stem cells, and the
emergence of epithelial-mesenchymal transition cells, which have increased metastatic
potential. It is through an enhanced understanding of these mechanisms that new thera¬
pies can be developed to combat this disease.
Advancing Prostate Cancer: Treatment Options for the Urologist
William T. Lowrance and Sam S. Chang
Today s urologists often face the dilemma of how to treat patients who have advancing
prostate cancer. The diversity of this patient population makes treatment decisions chal¬
lenging. For over
prostate cancer has been androgen deprivation therapy. Now there are new chemother-
apeutic options, novel hormone manipulations, and other adjunctive therapies available.
Based on a case presentation, the authors have attempted to outline for the practicing
urologist, a logical progression of treatment options for advancing prostate cancer.
Radiation Therapy and Radio-nuclides for Palliation of Bone Pain
Juanita
Bone pain from metastatic prostate cancer can be effectively palliated by a single fraction
of
schemes. Re-treatment, if required, is simple and effective. For multiple painful sites on
the same side of the diaphragm, hemi-body radiotherapy is rapidly effective; pre-med-
ication with odanstetron and steroids has markedly improved tolerance. For multiple
painful sites on both sides of the diaphragm, radiopharmaceuticals can be considered
but will not treat adjacent soft tissue disease or neurologic compromise.
Changing Perspectives of the Role of Chemotherapy in Advanced Prostate
Cancer
Earle F. Burgess and Bruce J. Roth
The use of cytotoxic chemotherapy in advanced prostate adenocarcinoma has been va¬
lidated by the recent demonstration of survival benefit in two large randomized phase III
trials. Before publication of these landmark trials, SWOG
motherapeutic regimen had shown survival benefit in the treatment of androgen inde¬
pendent prostate cancer (AIPC). These trials provide new encouragement for the use
of chemotherapy in all stages of disease. Improved communication between medical
and
essential for identifying new chemotherapeutie regimens with improved activity in
AIPC and for defining the role of chemotherapy in earlier-stage disease. This article dis¬
cusses the role of chemotherapy as the current standard of care for the treatment of AIPC
and provides a historical perspective of the trials that preceded the development of cur¬
rent docetaxel-based regimens.
CONTENTS
Complementary and Alternative Medicine for Advanced Prostate Cancer
J.
Complimentary and alternative medicines (CAM) have increased drastically in popular¬
ity in the past decade. These are largely in the form of nutritional supplements. Despite a
wealth of information sources on the subject, the fundamental problem with CAM thera¬
pies is a dearth of evidence-based medicine. Advanced prostate cancer has significant
long-term morbidity, and there is a growing interest in alternative and complimentary
forms of therapy that will improve the outcomes of patients who have recurrent or
advanced prostate cancer while obviating the need for more toxic forms of therapy. In
this article we summarize the use of some of the more common CAM nutritional supple¬
ments and review the scientific data that are available to support their use.
Future Innovations in Treating Advanced Prostate Cancer
Pratik Desai,
Many novel techniques for the treatment of prostate cancer are being aggressively inves¬
tigated because prostate cancer is prevalent in the population and the current treatments
for advanced prostate cancer are woefully inadequate. Although the current treatment
options prolong life, most patients will eventually experience local recurrence or develop
advanced disease. A greater understanding of the molecular events underlying cancer
has enabled investigators to explore gene therapy approaches that are targeted against
these molecular events. This article discusses antiangiogenic therepy, immune based
therapy, and gene therapy. Any of these experimental modalities could be developed
to replace hormone ablation therapy which causes unpleasant side effects, decreases
the quality of life of the patient, and only temporarily controls the disease.
Index
CONTENTS
|
| adam_txt |
NEW APPROACHES IN THE TREATMENT OF ADVANCED PKOSTATK CANCER
CONTENTS
Foreword xi
Martin I. Resnick
Preface xiii
Joseph A. Smith, Jr and Sam S. Chang
The Evolution of Imaging in Advanced Prostate Cancer
Michael J. Manyak,
and Erik S. Storm
Medical advances will be driven by the enhancement of imaging for diagnosis, refine¬
ment of treatment, and evaluation of treatment efficacy. The convergence of technology
in materials science, biology, and the computer industry has greatly advanced diagnostic
imaging. Precision in control of the spatial and temporal properties of light and its het¬
erogeneous scattering properties have extended our capability for imaging. Refinements
in radioimmunoscintigraphy for image acquisition, fusion of images, and outcome data
now suggest use for image-guided therapy. Novel MRI agents appear to provide signif¬
icant imaging capabilities to detect malignant lymph nodes. Future applications of opti¬
cal coherence tomography, electron paramagnetic resonance imaging, nanotechnology,
molecular imaging, and hyperspectral spectroscopy promise further refinements to
image tissues for diagnosis.
Biochemical Recurrence after Localized Treatment
Christopher L. Amling
The quoted incidence of biochemical recurrence (BCR) after localized treatment varies
significantly and depends on numerous well-known prognostic factors; however, it
likely occurs in at least 30%-40% of patients who receive localized treatment. Because
the clinical significance of BCR is often unclear, and depends in many cases on unknown
factors, it is difficult to select the best treatment and determine when best to institute that
therapy. This review examines some of the issues associated with BCR and attempts to
shed some light on this common but controversial clinical scenario. Some treatment stra¬
tegies discussed in this article include salvage radiotherapy after radical prostatectomy,
salvage therapy after radiotherapy, and hormonal therapy.
Combined Androgen Blockade: An Update
Laurence
The use of combined androgen blockade therapy in prostate cancer management re¬
mains controversial. This article reviews the effect of the different non-steroid androgens
VOLUME
in blocking androgen-independent activation of the androgen receptor in the androgen-
depleted environment, and the potential benefit of bicalutamide in comparison to the
first generation of anti-androgens (flutamide and nilutamide). An estimate of the benefit
of combined therapy with bicalutamide suggests there is a high probability that bicalu¬
tamide
This treatment must be balanced against the potential for an increase in side-effects and a
consequent adverse effect on the patient's quality of
Intermittent Androgen Deprivation: Clinical Experience and Practical
Applications
Jonathan L. Wright, Celestia S. Higano, and Daniel W. Lin
Prostate cancer is more frequently being diagnosed at an earner age, men are dying of
prostate cancer at an older age, and men are now treated with androgen deprivation
for biochemical relapse. As a result, the amount of time that patients are potentially sub¬
jected to androgen deprivation is increasing. Intermittent androgen deprivation (IAD)
has been investigated as a potential alternative to continuous androgen deprivation
(CAD) in order to improve quality of
gen independence. Along with the increased use of primary hormonal therapy in clini¬
cally localized prostate cancer, IAD may supplant the traditional surgical or
radiotherapy options, specifically in men who have underlying co-morbidities and de¬
creased
lend insight into the utility, efficacy, and feasibility of IAD versus CAD. This article dis¬
cusses the theoretical benefits and rationale of IAD and reviews the completed and on¬
going IAD trials. Finally, the controversies, practical applications, and future directions
of IAD are addressed.
Managing Complications of Androgen Deprivation Therapy
for Prostate Cancer
Jeffrey M. Holzbeierlein
With the increase in the number of prostate cancer cases seen in the United States, the use
of androgen deprivation therapy (ADT) as a form of treatment has continued to rise.
With the increasing use of ADT, it is important for the urologist to recognize the potential
side effects from the use of ADT and ways in which to minimize or
from these side effects. This article describes the potential complications of ADT and
the recommendations for treatment or prevention of these complications. In addition,
we examine the role of nontraditional forms of ADT and the potential benefits they offer.
The Role of Bisphosphonates in Preventing Skeletal Complications
of Hormonal Therapy
Scott M. Gilbert and James M. McKiernan
Androgen deprivation therapy (ADT) is associated with a significant decrease in bone
mineral density (BMD), and continued exposure seems to increase the risk of osteoporo-
tic fracture in men who have prostate cancer treated with this strategy. Men who have
prostate cancer may have low BMD before initiation of ADT. Bisphosphonates are pyr-
ophosphate analogs that decrease bone
osteoclast activity and proliferation. Several bisphosphonates have been evaluated in
randomized clinical trials, and the cumulative data show that these medications increase
or maintain BMD in men receiving ADT for prostate cancer. The effect on clinical frac¬
tures has not been assessed adequately, but bisphosphonates offer an important potential
treatment modality to reduce the risk of osteoporotic fracture in this population of men.
CONTENTS
Mechanisms Leading to the Development of Hormone-Resistant
Prostate Cancer
Susan
Advanced and metastatic prostate cancers remain potentially lethal tumors. Although
androgen deprivation therapy remains the most effective treatment, patients who pro¬
gress to androgen independence die of their disease. This article focuses on the mechan¬
isms by which hormone resistance develops, including the reactivation of androgen
receptor during androgen deprivation therapy, the role of cancer stem cells, and the
emergence of epithelial-mesenchymal transition cells, which have increased metastatic
potential. It is through an enhanced understanding of these mechanisms that new thera¬
pies can be developed to combat this disease.
Advancing Prostate Cancer: Treatment Options for the Urologist
William T. Lowrance and Sam S. Chang
Today's urologists often face the dilemma of how to treat patients who have advancing
prostate cancer. The diversity of this patient population makes treatment decisions chal¬
lenging. For over
prostate cancer has been androgen deprivation therapy. Now there are new chemother-
apeutic options, novel hormone manipulations, and other adjunctive therapies available.
Based on a case presentation, the authors have attempted to outline for the practicing
urologist, a logical progression of treatment options for advancing prostate cancer.
Radiation Therapy and Radio-nuclides for Palliation of Bone Pain
Juanita
Bone pain from metastatic prostate cancer can be effectively palliated by a single fraction
of
schemes. Re-treatment, if required, is simple and effective. For multiple painful sites on
the same side of the diaphragm, hemi-body radiotherapy is rapidly effective; pre-med-
ication with odanstetron and steroids has markedly improved tolerance. For multiple
painful sites on both sides of the diaphragm, radiopharmaceuticals can be considered
but will not treat adjacent soft tissue disease or neurologic compromise.
Changing Perspectives of the Role of Chemotherapy in Advanced Prostate
Cancer
Earle F. Burgess and Bruce J. Roth
The use of cytotoxic chemotherapy in advanced prostate adenocarcinoma has been va¬
lidated by the recent demonstration of survival benefit in two large randomized phase III
trials. Before publication of these landmark trials, SWOG
motherapeutic regimen had shown survival benefit in the treatment of androgen inde¬
pendent prostate cancer (AIPC). These trials provide new encouragement for the use
of chemotherapy in all stages of disease. Improved communication between medical
and
essential for identifying new chemotherapeutie regimens with improved activity in
AIPC and for defining the role of chemotherapy in earlier-stage disease. This article dis¬
cusses the role of chemotherapy as the current standard of care for the treatment of AIPC
and provides a historical perspective of the trials that preceded the development of cur¬
rent docetaxel-based regimens.
CONTENTS
Complementary and Alternative Medicine for Advanced Prostate Cancer
J.
Complimentary and alternative medicines (CAM) have increased drastically in popular¬
ity in the past decade. These are largely in the form of nutritional supplements. Despite a
wealth of information sources on the subject, the fundamental problem with CAM thera¬
pies is a dearth of evidence-based medicine. Advanced prostate cancer has significant
long-term morbidity, and there is a growing interest in alternative and complimentary
forms of therapy that will improve the outcomes of patients who have recurrent or
advanced prostate cancer while obviating the need for more toxic forms of therapy. In
this article we summarize the use of some of the more common CAM nutritional supple¬
ments and review the scientific data that are available to support their use.
Future Innovations in Treating Advanced Prostate Cancer
Pratik Desai,
Many novel techniques for the treatment of prostate cancer are being aggressively inves¬
tigated because prostate cancer is prevalent in the population and the current treatments
for advanced prostate cancer are woefully inadequate. Although the current treatment
options prolong life, most patients will eventually experience local recurrence or develop
advanced disease. A greater understanding of the molecular events underlying cancer
has enabled investigators to explore gene therapy approaches that are targeted against
these molecular events. This article discusses antiangiogenic therepy, immune based
therapy, and gene therapy. Any of these experimental modalities could be developed
to replace hormone ablation therapy which causes unpleasant side effects, decreases
the quality of life of the patient, and only temporarily controls the disease.
Index
CONTENTS |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author_GND | (DE-588)1024897761 |
| building | Verbundindex |
| bvnumber | BV021611216 |
| classification_rvk | YK 7500 |
| ctrlnum | (OCoLC)255666165 (DE-599)BVBBV021611216 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01565nam a2200373 cb4500</leader><controlfield tag="001">BV021611216</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20140207 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">060608s2006 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">141603563X</subfield><subfield code="9">1-4160-3563-X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)255666165</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV021611216</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YK 7500</subfield><subfield code="0">(DE-625)153783:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New approaches in the treatment of advanced prostate cancer</subfield><subfield code="c">guest ed. Joseph A. Smith ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIII S., S. 133 - 278</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Urologic clinics of North America</subfield><subfield code="v">33,2</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Prostatakrebs</subfield><subfield code="0">(DE-588)4047511-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Prostatakrebs</subfield><subfield code="0">(DE-588)4047511-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smith, Joseph A.</subfield><subfield code="d">1949-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)1024897761</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Urologic clinics of North America</subfield><subfield code="v">33,2</subfield><subfield code="w">(DE-604)BV000001584</subfield><subfield code="9">33,2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UBRegensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014826424&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-014826424</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV021611216 |
| illustrated | Illustrated |
| index_date | 2024-07-02T14:50:36Z |
| indexdate | 2024-07-09T20:39:51Z |
| institution | BVB |
| isbn | 141603563X |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-014826424 |
| oclc_num | 255666165 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-29 DE-19 DE-BY-UBM |
| owner_facet | DE-355 DE-BY-UBR DE-29 DE-19 DE-BY-UBM |
| physical | XIII S., S. 133 - 278 Ill., graph. Darst. |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | Saunders |
| record_format | marc |
| series | Urologic clinics of North America |
| series2 | Urologic clinics of North America |
| spelling | New approaches in the treatment of advanced prostate cancer guest ed. Joseph A. Smith ... Philadelphia [u.a.] Saunders 2006 XIII S., S. 133 - 278 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Urologic clinics of North America 33,2 Therapie (DE-588)4059798-2 gnd rswk-swf Prostatakrebs (DE-588)4047511-6 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Prostatakrebs (DE-588)4047511-6 s Therapie (DE-588)4059798-2 s b DE-604 Smith, Joseph A. 1949- Sonstige (DE-588)1024897761 oth Urologic clinics of North America 33,2 (DE-604)BV000001584 33,2 Digitalisierung UBRegensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014826424&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | New approaches in the treatment of advanced prostate cancer Urologic clinics of North America Therapie (DE-588)4059798-2 gnd Prostatakrebs (DE-588)4047511-6 gnd |
| subject_GND | (DE-588)4059798-2 (DE-588)4047511-6 (DE-588)4143413-4 |
| title | New approaches in the treatment of advanced prostate cancer |
| title_auth | New approaches in the treatment of advanced prostate cancer |
| title_exact_search | New approaches in the treatment of advanced prostate cancer |
| title_exact_search_txtP | New approaches in the treatment of advanced prostate cancer |
| title_full | New approaches in the treatment of advanced prostate cancer guest ed. Joseph A. Smith ... |
| title_fullStr | New approaches in the treatment of advanced prostate cancer guest ed. Joseph A. Smith ... |
| title_full_unstemmed | New approaches in the treatment of advanced prostate cancer guest ed. Joseph A. Smith ... |
| title_short | New approaches in the treatment of advanced prostate cancer |
| title_sort | new approaches in the treatment of advanced prostate cancer |
| topic | Therapie (DE-588)4059798-2 gnd Prostatakrebs (DE-588)4047511-6 gnd |
| topic_facet | Therapie Prostatakrebs Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014826424&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000001584 |
| work_keys_str_mv | AT smithjosepha newapproachesinthetreatmentofadvancedprostatecancer |